Episode 245: Retatrutide Delivers Bariatric-Level Weight Loss: Breaking Down the TRIUMPH-1 Trial from ADA 2026

Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning.

In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available.

Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now!

Episode Highlights:

Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors

Participants lost an average of 28.3% of their body weight in 80 weeks

Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight

Nearly everyone with prediabetes reversed it and returned to normal blood sugar

Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity

The highest discontinuation rate due to side effects was only 11%—mainly GI issues

Retatrutide is not yet FDA approved but anticipated to launch early 2027

Connect with Dr. Alicia Shelly: